The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Clinical research

EXCELLA™ First-in-Man (FIM) study: safety and efficacy of novolimus-eluting stent in de novo coronary lesions


1. Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil; 2. Elixir Medical, Sunnyvale, California, USA; 3. Auckland City Hospital, Auckland, New Zealand; 4. Stanford University Medical Center, Stanford, California, USA

Aims: First generation DES have markedly reduced restenosis. However, there is a major interest in developing new DES with greater flexibility, radiopacity and safety profile. The Elixir Me

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
Biodegradable-polymer-based, sirolimus-eluting Supralimus® stent: 6-month angiographic and 30-month clinical follow-up results from the Series I prospective study